Innovative platform to screen CAR-T/TCR cancer immunotherapy drugs for off-target binding

轨道探索有限公司成立于2015年11月，是从牛津大学剥离出来的。创始IP涉及一种肽展示平台及其在高通量屏幕中用于鉴定新肽和鉴定T细胞表位的用途。我们为一系列慢性病提供识别和表征先进疗法的服务。**目标市场**制造改良TCR作为癌症免疫治疗药物产品的公司目前迫切需要确定其产品的脱靶结合，以确保安全性；临床试验中已有几例患者因直接使用改良TCR治疗而死于心脏或胃炎。**项目说明**该项目旨在调查和验证广泛的筛查解决方案，使这些公司能够更全面、更可靠地在开发早期筛选其产品。这将减少临床试验期间出现医学副作用或死亡的风险，并将加快开发和部署更有效的癌症治疗方法。

Orbit Discovery Ltd was established in November 2015 as a spin-out from Oxford University. The founding IP relates to a peptide display platform and its use for the identification of novel peptides and for the identification of T-cell epitopes in high throughput screens. We provide services identifying and characterising advanced therapeutics for a range of chronic diseases.**Target Markets**Companies making modified TCRs as drug products for Cancer Immunotherapy have a current pressing need to identify off-target binding of their products to ensure safety; there have been several reported patient deaths in clinical trials due to cardiac or gastric inflammation as a direct result of treatment with modified TCRs.**Project Description**This project aims to investigate and validate a broad screening solution that would enable these companies to more comprehensively and reliably screen their products earlier in development. This would reduce the risk of medical side-effects or fatalities during clinical trials and would speed up the development and deployment of more effective cancer treatments.